lenacapavir + teropavimab + zinlirvimab

**lenacapavir + teropavimab + zinlirvimab** is an investigational combination regimen for HIV-1 treatment, composed of one small-molecule capsid inhibitor (lenacapavir) and two broadly neutralizing monoclonal antibodies (teropavimab and zinlirvimab). Lenacapavir blocks HIV-1 replication by inhibiting the viral capsid protein, disrupting multiple key stages of the viral lifecycle. Teropavimab targets the CD4-binding site on the HIV-1 envelope glycoprotein, while zinlirvimab targets the V3 loop glycan region. Both monoclonal antibodies neutralize HIV-1 and mediate immune effector functions, including targeted killing of infected cells. All three agents have engineered long half-lives, allowing for potential twice-yearly (every six months) dosing. The regimen is being developed as a long-acting, convenient alternative to daily antiretroviral therapy for people living with HIV, with the primary aim to maintain durable HIV suppression and improve therapy adherence. Phase 1b and phase 2 trials have shown maintenance of virologic suppression in most virologically suppressed adults switched to this regimen, with a good safety profile and no serious adverse events[1][2][3][5][7].

Other names

LENTABZAB